A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Brodalumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-3
  • Sponsors Amgen
  • Most Recent Events

    • 28 Feb 2018 Results of an integrated analysis of AMAGINE-2 and AMAGINE-3 trials assessing the impact of previous biologic exposure on efficacy and safety of brodalumab and ustekinumab (n=493), published in the British Journal of Dermatology
    • 16 Feb 2018 Pooled results from AMAGINE 1, 2 and trials presented at the 76th annual American Academy of Dermatology meeting according to a LEO Pharma media release.
    • 12 Oct 2017 Results of pooled analysis of AMAGINE 2 and 3 trial presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top